Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy

Epilepsy Research

Volumn 40, Issue 1, 2000, Pages 7-15

  Tamura, Tsunenobu ^a   Aiso, Kenji ^a   Johnston, Kelley E ^a   Black, Lori ^b   Faught, Edward ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antiepileptic drugs; Folate; Homocysteine; Humans; Vitamin B 12; Vitamin B 6

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LAMOTRIGINE; PHENYTOIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; VALPROIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPILEPSY; ERYTHROCYTE LEVEL; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK; VITAMIN BLOOD LEVEL;

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADULT; AGED; ANTICONVULSANTS; DRUG STABILITY; FEMALE; FOLIC ACID; GENOTYPE; HEAT; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OSMOLAR CONCENTRATION; OXIDOREDUCTASES; PYRIDOXINE; VITAMIN B 12;

EID: 0034212375     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(00)00101-7     Document Type: Article

References (40)

1. Annegers J.F., Hauser W.A., Shirts S.B. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia. 25:1984;699-704.
2. Arakawa T., Honda Y., Narisawa K. Mechanism of decreased in serum folate levels of rats receiving diphenylhydantoin. Tohoku J. Exp. Med. 111:1973;203-210.
3. Billings R.E. Decreased hepatic 5,10-methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment. Mol. Pharmacol. 25:1984;459-466.
4. Camp V.M., Chipponi J., Faraj B.A. Radioenzymatic assay for direct measurement of plasma pyridoxal-5′-phosphate. Clin. Chem. 29:1983;642-644.
5. Carl G.F., Smith D.B. The effect of chronic phenytoin treatment on tissue folate concentrations and on the activities of the methyl synthetic enzymes in the rat. J. Nutr. 113:1983;2368-2374.
6. Carl G.F., Smith M.L. Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations. Epilepsia. 30:1989;217-224.
7. Chanarin I., Laidlaw J., Loughridge L.W., Mollin D.L. Megaloblastic anaemia due to phenobarbitone. The convulsant action of therapeutic doses of folic acid. Br. Med. J. i:1960;1099-1102.
8. Craig J., Morrison P., Morrow J., Patterson V. Failure of periconceptional folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure. 8:1999;253-254.
9. Dasheiff R.M. Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation on the relationship to sudden cardiac death. J. Clin. Neurophysiol. 8:1991;216-222.
10. 12, and folic acid, proteins, and fine structure of liver. Epilepsia. 28:1987;147-159.
11. Finkelstein J.D. Methionine metabolism in mammals. J. Nutr. Biochem. 1:1990;228-237.
12. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J.H., den Heijer M., Kluijtmans L.A.J., van den Heuvel L.P., Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
13. Goggin T., Gough H., Bissessar A., Crowley M., Baker M., Callaghan N. A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy. Quart. J. Med. 247:1987;911-919.
14. Hauser E., Seidl R., Freilinger M., Male C., Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 18:1996;105-109.
15. Hendel J., Dam M., Gram L., Winkel P., Jørgensen I. The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol. Scand. 69:1984;226-231.
16. Herbert V. Development of human folate deficiency. Picciano M.F., Stokstad E.L.R., Gregory J.F. III Folic Acid Metabolism in Health and Disease. 1990;190-210 Wiley-Liss, New York.
17. Hoffbrand A.V., Necheles T.F. Mechanism of folate deficiency in patients receiving phenytoin. Lancet. ii:1968;528-530.
18. James G.K., Jones M.W., Pudek M.R. Homocyst(e)ine levels in patients on phenytoin therapy. Clin. Biochem. 30:1997;647-649.
19. Krause K.-H., Bonjour J.-P., Berlit P., Kynast G., Schmidt-Gayk H., Schellenberg B. Effect of long-term treatment with antiepileptic drugs on the vitamin status. Drug-Nutr. Interact. 5:1988;317-343.
20. Lewis D.P., Van Dyke D.C., Willhite L.A., Stumbo P.J., Berg M.J. Phenytoin-folic acid interaction. Ann. Pharmacother. 29:1995;726-735.
21. Li X., Breteler M.M.B., de Bruyne M.C., Meinardi H., Hauser W.A., Hofman A. Vascular determinants of epilepsy: the Rotterdam study. Epilepsia. 38:1997;1216-1220.
22. Luoma P.V., Myllylä V.V., Sotaniemi E.A., Lehtinen I.A., Hokkanen E.J. Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur. Neurol. 19:1980;67-72.
23. 12 levels in anticonvulsant therapy. Br. Med. J. i:1966;955-957.
24. May R.B., Sunder T.R. Hematologic manifestations of long-term valproate therapy. Epilepsia. 34:1993;1098-1101.
25. Miller A.A., Sawyer D.A., Roth B. Lamotrigine. Meldrum B.S., Porter R.J. New Anticonvulsant Drugs. 1986;165-177 John Libby, London.
26. Morgan S.L., Baggott J.E., Lee J.Y., Alarcon G.S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: implication for cardiovascular disease prevention. J. Rheumatol. 25:1998;441-446.
27. MRC Vitamin Study Research Group, 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338, 131-136.
28. Ono H., Sakamoto A., Eguchi T., Fujita N., Nomura S., Ueda H., Sakura N., Ueda K. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 46:1997;959-962.
29. Preece J., Reynolds E.H., Johnson A.L. Relation of serum to red cell folate concentrations in drug-treated epileptic patients. Epilepsia. 12:1971;335-340.
30. Refsum H., Ueland P.M., Nygård O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 49:1998;31-62.
31. Reynolds E.H. Chronic antiepileptic toxicity: a review. Epilepsia. 16:1975;319-352.
32. Rosenberg I.H., Godwin H.A., Streiff R.R., Castle W.B. Impairment of intestinal deconjugation of dietary folate. A possible explanation of megaloblastic anaemia associated with phenytoin therapy. Lancet. ii:1968;530-532.
33. Sander J.W.A.S., Patsalos P.N. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. 13:1992;89-92.
34. Schwaninger M., Ringleb P., Winter R., Kohl B., Fiehn W., Reiser P.A., Walter-Sack I. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 40:1999;345-350.
35. Stabler S.P., Marcell P.D., Podell E.R., Allen R.H. Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal. Biochem. 162:1987;185-189.
36. Stevenson R.E., Schwartz C.E., Du Y.-Z., Adams M.J. Jr Difference in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am. J. Med. Gen. 60:1997;229-230.
37. Tamura T. Microbiological assay of folates. Picciano M.F., Stokstad E.L.R., Gregory J.F. Folic Acid Metabolism in Health and Disease. 1990;121-137 Wiley-Liss, New York.
38. Tamura T., Bergman S.M., Morgan S.L. Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis. Am. J. Kidney Dis. 32:1998;475-481.
39. Tamura T., Johnston K.E., Bergman S.M. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J. Am. Soc. Nephrol. 7:1996;2414-2418.
40. Yoo J.-H., Hong S.B. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism. 48:1999;1047-1051.